Mr Prondzynski brings strong executive management and diverse global experience from leadership positions held at multinational healthcare companies. The addition of Mr Prondzynski expands Hospira’s board to 10 directors, of whom nine are independent.
Mr Prondzynski has served as CEO of Roche Diagnostics and as a member of the executive committee of F Hoffman-La Roche from early 2000 to 2005, retiring from Roche at the end of 2006. Mr Prondzynski is on the boards of Koninklijke Philips Electronics, Qiagen, BB Medtech and Epigenomics.
Christopher Begley, chairman and CEO of Hospira, said: “Heino has an impressive track record of achievement in the healthcare industry and significant experience in delivering global growth and expansion. His interest in talent development and passion for driving product innovation also make him an excellent and complementary addition to the Hospira board.”